Investors focused on a 0.9% decline in U.S. treatment volumes, overshadowing stronger-than-expected financial results.
Fresenius Medical Care (FMS) shares fell 8.0% to €41.285 as markets reacted to a 0.9% year-over-year drop in U.S. same-market treatment volumes. The decline offset better-than-expected earnings, raising concerns about future growth in its largest market.
The company reported Q2 operating income of €569 million, up 23% on a currency-adjusted basis, surpassing the €515 million consensus. Revenue reached €4.861 billion, exceeding forecasts of €4.792 billion. Despite the beat, investor sentiment remained cautious.
JPMorgan maintained an “Underweight” rating on the stock with a €37.40 price target, reflecting ongoing skepticism about operational trends.